Semaglutide reduces HbA<sub>1c</sub> and body weight across baseline HbA<sub>1c</sub> subgroups in the SUSTAIN 1-5 clinical trials - Virtual Meeting | EASD
Jagjit Singh Bains - Manager, Annual Product Quality Review, Quality Systems - Sanofi Pasteur | LinkedIn
![PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2022 - EORTC PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2022 - EORTC](https://www.eortc.org/app/uploads/2021/06/Ameera-study_EORTC-Sanofi-BIG-AFT.jpg)